Who
Frank L. Jaksch Jr.
Director
Company insider
Files Form 4 as: Executive Chairman of Board, Niagen Bioscience.
In numbers
- Trades disclosed
- 65
- Buys
- 11
- Sells
- 8
- Bought
- $131K
- Sold
- $1.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Oct 2008
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 24 Jun 2025filed 25 Jun 2025 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Dec 2024filed 13 Dec 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,001 at $0.00 | filing |
| 13 Dec 2024filed 13 Dec 2024 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $183K50,001 at $3.66 | filing |
| 13 Dec 2024filed 13 Dec 2024 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Sold | $230K37,161 at $6.19 | filing |
| 20 Jun 2024filed 21 Jun 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 Jun 2023filed 13 Jun 2023 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Bought | $12K7,000 at $1.69 | filing |
| 17 Feb 2022filed 22 Feb 2022 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —107,805 at $0.00 | filing |
| 15 Mar 2021filed 17 Mar 2021 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,072 at $0.00 | filing |
| 10 Dec 2020filed 11 Dec 2020 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —41,667 at $0.00 | filing |
| 10 Dec 2020filed 11 Dec 2020 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $193K41,667 at $4.62 | filing |
| 10 Dec 2020filed 11 Dec 2020 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Sold | $196K37,829 at $5.19 | filing |
| 25 Feb 2020filed 6 Nov 2020 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —74,048 at $0.00 | filing |
| 25 Feb 2020filed 27 Feb 2020 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —74,048 at $0.00 | filing |
| 11 Mar 2019filed 12 Mar 2019 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —33,334 at $0.00 | filing |
| 11 Mar 2019filed 12 Mar 2019 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $50K33,334 at $1.50 | filing |
| 11 Mar 2019filed 12 Mar 2019 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Sold | $50K14,390 at $3.50 | filing |
| 21 Feb 2019filed 22 Feb 2019 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —55,040 at $0.00 | filing |
News
Restore Hyper Wellness® and Niagen Bioscience Team Up to Help Americans Age Better This OctoberNAGE · prnewswire.com · 8 Oct 2026
0 headlines in the last 90 days name Frank L. Jaksch Jr.; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.